Table 4

Outcome of treatment with intravitreal anti-VEGF injection (n=30)

Stabilisation , no recurrences19 (63.33%)
Average number of injections per eye2.11
Active lesion improving with treatment*3 (10%)
Recurrent lesion improving with treatment†2 (6.66%)
Stabilisation after repeat anti-VEGF for recurrence3 (10%)
Stabilisation with treatment other than anti-VEGF after initial recurrence3 (10%)
Number of eyes that stabilised with a single dose of anti-VEGF of any kind6 (20%)
Eyes with recurrences when treated on PRN basis2 (out of 8), 25%
Eyes with recurrence when treated with (three)  monthly loading doses3 (out of 10), 30%
Gain in visual acuity (logMAR) after complete CNVM regression at last follow-up following intravitreal anti-VEGF: subgroup analysis based on location
 Subfoveal (n=14)0.4361−0.3310 to 1.300
 Extrafoveal (n=3)0.0780−0.0669 to 0.1761
 Peripapillary (n=5)0.77520.1770 to 1.699
 Juxtafoveal (n=3)0.19130 to 0.3979
P value0.1993
Overall gain in visual acuity (logMAR) with intravitreal anti-VEGF treatment in the loading and PRN groups
Loading group (n=10)PRN group (n=8)
 Range−0.3310 to 1.700−0.1540 to 1.301
P value0.2299
  • *Active lesion improving with treatment indicates that CNVM was improving with each anti-VEGF injection but has not completely regressed, in contrast to recurrence, which was defined as reactivation after the lesion became inactive with treatment.

  • †The lesion became inactive with treatment but demonstrated recurrent activity and required treatment until last study visit.

  • CNVM, choroidal neovascular membrane; PRN, pro re nata; VEGF, vascular endothelial growth factor.